AI-Powered Pathology Collaboration Supports Companion Diagnostic Development

The collaboration will enable pharmaceutical companies, diagnostic assay and platform providers, and contract research organizations to combine quantitative pathology workflows with centralized image and data management. By bringing these capabilities into a unified environment, the integration aims to reduce workflow fragmentation and support more consistent execution across research, clinical development, validation, and deployment.

Imagene AI’s IHC capabilities apply advanced AI to quantify biomarker expression and spatial characteristics that can be difficult to capture with conventional scoring. Features include high-definition cell and subcellular segmentation, tools that identify feature combinations distinguishing clinical populations, options for continuous and advanced spatial scoring, and stratification utilities for analyzing patient cohorts. In parallel, H&E-based patient screening can be used to inform molecular testing, complementing established tissue-diagnostic workflows with AI-powered image analysis.

By making these capabilities accessible within Concentriq, organizations can incorporate quantitative pathology into biomarker strategies and clinical development programs at scale. Concentriq is used by 16 of the top 20 pharmaceutical companies and leading contract research organizations and provides a good practice (GxP) environment for building and validating algorithms that can then be deployed across global trials on the same platform. As the platform is also used by diagnostic laboratories managing millions of patient cases each year, it can help carry validated diagnostics from approval to broad clinical adoption.

Proscia Ready brings together interoperable technologies and coordinated customer support to help diagnostic laboratories and life sciences organizations scale digital pathology while reducing the complexity of managing multi‑vendor solutions. The alliance offers a shared framework for continued innovation and enables future collaborations between Imagene AI and Proscia. The collaboration provides a scalable foundation for sponsors, diagnostic providers, and contract research organizations to operationalize AI‑powered IHC workflows across global laboratory networks.

“Developing a companion diagnostic requires pharmaceutical companies, diagnostic providers, and CROs to operate as one connected ecosystem. By joining Proscia Ready, we are making it easier to integrate advanced AI image analysis into established pathology workflows and scale IHC companion diagnostic programs from biomarker strategy through clinical development and deployment,” said Michael Hreczuck, SVP of Business Development at Imagene AI.

“Companion diagnostic development depends on bringing specialized expertise and technology together. Imagene AI expands the advanced quantitative image analysis and deep precision-oncology capabilities available through Proscia Ready. Together, we can help more pharmaceutical companies and their diagnostic and laboratory partners efficiently operationalize AI-powered IHC workflows, from biomarker strategy to clinical impact,” said Stephan Fromme, Head of Business Development at Proscia.

Related Links
Imagene AI
Proscia